Does AXITINIB Cause Second primary malignancy? 117 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 117 reports of Second primary malignancy have been filed in association with AXITINIB (INLYTA). This represents 0.7% of all adverse event reports for AXITINIB.
117
Reports of Second primary malignancy with AXITINIB
0.7%
of all AXITINIB reports
10
Deaths
28
Hospitalizations
How Dangerous Is Second primary malignancy From AXITINIB?
Of the 117 reports, 10 (8.5%) resulted in death, 28 (23.9%) required hospitalization, and 2 (1.7%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for AXITINIB. However, 117 reports have been filed with the FAERS database.
What Other Side Effects Does AXITINIB Cause?
Death (2,222)
Diarrhoea (2,187)
Fatigue (1,816)
Neoplasm progression (1,315)
Hypertension (1,146)
Off label use (1,075)
Nausea (955)
Decreased appetite (920)
Dysphonia (871)
Disease progression (768)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which AXITINIB Alternatives Have Lower Second primary malignancy Risk?
AXITINIB vs AZACITIDINE
AXITINIB vs AZATHIOPRINE
AXITINIB vs AZD-1222
AXITINIB vs AZELAIC ACID
AXITINIB vs AZELASTINE